STEM CELL- mit STEM CELL gute Kursgewine erzielen

Seite 49 von 50
neuester Beitrag:  20.08.21 09:59
eröffnet am: 21.01.10 14:04 von: brunneta Anzahl Beiträge: 1236
neuester Beitrag: 20.08.21 09:59 von: Bigbqq Leser gesamt: 202615
davon Heute: 20
bewertet mit 12 Sternen

Seite:  Zurück   48  |    50    von   50     
13.01.12 17:47 #1201 was bitte sind denn schon
1.225.000 Stücke bei so einem Rotzkurs???

Ich wünschte hier würde mal was platzen...aber da seh ich weit und breit nix...  
18.01.12 19:40 #1202 Es wäre höchste Zeit für eine Monster-Explo.
18.01.12 19:45 #1203 Von 0.0001 auf 0.01
wären wieviel Prozent?  
18.01.12 19:48 #1204 US Pennystocks sind mega INN
also ran an den Speck, bevor die Ammies den Braten riechen  
18.01.12 21:27 #1205 Graefe, wo willst du die denn handeln?
20.01.12 08:44 #1206 gibt es irgendwelche News zu SCLL ???
Kann vielleicht jemand eine kurze Zusammenfassung erstellen was genau mit SCLL passiert ist und wie es weitergeht?

Meinen Dank vorab!  
20.01.12 08:44 #1207 Sind die noch handelbar?
20.01.12 15:57 #1208 Mann oder Frau kann nie genau vorhersagen
wann dieses Teil bei den Amies explodiert?!!  
31.01.12 17:11 #1209 Explodiert?!
wär schon schön, wenn es mal zucken würde!
Ich glaub nicht mehr recht dran :-(  
31.01.12 19:16 #1210 wie und wo wird hier noch gehandelt???
in meinem Depot sind sie zwar noch eingebucht, aber aber es gibt keinen Handelsplatz und somit keine Kurse...  
01.02.12 19:19 #1211 @alle Anleger
es gibt Hoffnung für alle Aktionäre!

Warum?

Jesus Christus ist auch wieder Auferstanden von den Toten!  
06.02.12 13:45 #1212 Alles ist möglich, siehe
US09059T2069 !  
07.02.12 23:39 #1213 SECURITIES EXCHANGE ACT OF 1934 Rel.
Kann mir jemand sagen, was dies bedeutet?

http://www.sec.gov/litigation/admin/2012/34-66240.pdf  
08.02.12 11:24 #1214 @Mehe
Das möchte ich auch wissen! Was bedeutet das?  
08.02.12 16:15 #1215 Letzter Absatz
Angesichts des Vorangehenden (STEMS CELLS) hält die Kommission es für notwendig und passend für den Schutz der Investoren, die Sanktionen aufzuerlegen.

XXXTRADER  
09.02.12 09:26 #1216 also Tod?!
09.02.12 09:30 #1217 Info
es wäre besser, die Aktionäre zu entschädigen, als dass die Firma von der entsprechenden Kommission Sanktionen auferlegt bekommt!  
09.02.12 10:56 #1218 ja wie jetzt ?
kann ev. jemand hier etwas genauer erklären was jetzt Sache ist ?
welche Sanktionen sollten das dann sein und was heißt das für uns ?
danke  
18.03.12 18:48 #1219 Global Data Report
Zumindest Global Data will an der Firma noch verdienen. Was es da wöhl noch zu analysieren gibt? das die Firma delistet ist wissen wir auch so. 250€, wer gibt die wohl aus?

Stem Cell Innovations, Inc. (SCLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published by GlobalData on Mar 05, 2012 , 23 pages


                    §Description Table of Contents
Stem Cell Innovations, Inc. (SCI) is a privately held biotechnology company, based in the US. The company is engaged in the discovery and development of human cell based drugs. Its core technologies concentrate on developing, growing, and manipulating human cells in the laboratory using proprietary technology. The company is into the development of a broad array of human primary cell models, which can be used as powerful research tools to form the basis of therapeutic breakthroughs. SCI has established many human pluripotent stem cell lines fetal gonadal tissue using defined conditions, and the PluriCell lines are established directly onto tissue culture plastic without using feeder layers or conditioned medium. The company also has in vitro hepatocyte screening, kits, compositions, and services for compound toxicity testing, ACTIVTox and PREDICTIVTox in store. SCI is headquartered at Houston in Texas, the US.

Stem Cell Innovations, Inc. (SCLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.

Scope

   Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
   Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
   Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
   Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
   Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
   Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
   Business Description - A brief description of the company's operations.
   Key Employees - A list of the key executives of the company.
   Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
   Key Competitors - A list of the key competitors of the company.
   Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

   The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

   The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

   Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

   The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

   Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

   Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.  
16.05.12 16:05 #1220 Sie zieht an mal wieder
16.05.12 16:08 #1221 ++++++%$
16.05.12 16:10 #1222 US62544S2005
so etwa?  
16.05.12 16:10 #1223 Sorry war falsch
16.05.12 16:11 #1224 Ja Multicell
16.05.12 16:14 #1225 wäre auch zu schön gewesen
aber vielleicht im Soge von MultiCell?  
Seite:  Zurück   48  |    50    von   50     
Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen:    


Bitte warten...